Abstract

The expression of annexin A2 (ANXA2) in nasopharyngeal carcinoma (NPC) cells induces the immunosuppressive response in dendritic cells; however, the oncogenic effect and clinical significance of ANXA2 have not been fully investigated in NPC cells. Immunohistochemical staining for ANXA2 was performed in 61 patients and the association with clinicopathological status was determined. Short hairpin (sh)RNA knockdown of ANXA2 was used to examine cellular effects of ANXA2, by investigating alterations in cell proliferation, migration, invasion, adhesion, tube-formation assay, and chemo- and radiosensitivity assays were performed. RT-qPCR, Western blotting, and immunofluorescence were applied to determine molecular expression levels. Clinical association studies showed that the expression of ANXA2 was significantly correlated with metastasis (p = 0.0326) and poor survival (p = 0.0256). Silencing of ANXA2 suppressed the abilities of cell proliferation, adhesion, migration, invasion, and vascular formation in NPC cell. ANXA2 up-regulated epithelial-mesenchymal transition associated signal proteins. Moreover, ANXA2 reduced sensitivities to irradiation and chemotherapeutic drugs. These results define ANXA2 as a novel prognostic factor for malignant processes, and it can serve as a molecular target of therapeutic interventions for NPC.

Original languageEnglish
Pages (from-to)26946-26959
Number of pages14
JournalOncotarget
Volume6
Issue number29
DOIs
Publication statusPublished - 2015

Fingerprint

Annexin A2
Annexins
Carcinogenesis
Therapeutics
Cell Proliferation
Nasopharyngeal carcinoma
Epithelial-Mesenchymal Transition
Radiation Tolerance
Immunosuppressive Agents
Cell Adhesion
Dendritic Cells
Small Interfering RNA
Cell Movement
Fluorescent Antibody Technique
Blood Vessels
Western Blotting
Staining and Labeling
Neoplasm Metastasis

Keywords

  • Annexin A2 (ANXA2)
  • Chemotherapy
  • Epithelial-mesenchymal transition (EMT)
  • Nasopharyngeal carcinoma (NPC)
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology

Cite this

Targeting annexin A2 reduces tumorigenesis and therapeutic resistance of nasopharyngeal carcinoma. / Chen, Chang Yu; Lin, Yong-Song; Chen, Chi Long; Chao, Pin Zhir; Chiou, Jeng Fong; Kuo, Chia Chun; Lee, Fei Peng; Lin, Yung Feng; Sung, Yu Hsuan; Lin, Yun Tien; Li, Chang Fan; Chen, Yin Ju; Chen, Chien Ho.

In: Oncotarget, Vol. 6, No. 29, 2015, p. 26946-26959.

Research output: Contribution to journalArticle

@article{21098381fa0944ecb7c780768fd17f30,
title = "Targeting annexin A2 reduces tumorigenesis and therapeutic resistance of nasopharyngeal carcinoma",
abstract = "The expression of annexin A2 (ANXA2) in nasopharyngeal carcinoma (NPC) cells induces the immunosuppressive response in dendritic cells; however, the oncogenic effect and clinical significance of ANXA2 have not been fully investigated in NPC cells. Immunohistochemical staining for ANXA2 was performed in 61 patients and the association with clinicopathological status was determined. Short hairpin (sh)RNA knockdown of ANXA2 was used to examine cellular effects of ANXA2, by investigating alterations in cell proliferation, migration, invasion, adhesion, tube-formation assay, and chemo- and radiosensitivity assays were performed. RT-qPCR, Western blotting, and immunofluorescence were applied to determine molecular expression levels. Clinical association studies showed that the expression of ANXA2 was significantly correlated with metastasis (p = 0.0326) and poor survival (p = 0.0256). Silencing of ANXA2 suppressed the abilities of cell proliferation, adhesion, migration, invasion, and vascular formation in NPC cell. ANXA2 up-regulated epithelial-mesenchymal transition associated signal proteins. Moreover, ANXA2 reduced sensitivities to irradiation and chemotherapeutic drugs. These results define ANXA2 as a novel prognostic factor for malignant processes, and it can serve as a molecular target of therapeutic interventions for NPC.",
keywords = "Annexin A2 (ANXA2), Chemotherapy, Epithelial-mesenchymal transition (EMT), Nasopharyngeal carcinoma (NPC), Radiotherapy",
author = "Chen, {Chang Yu} and Yong-Song Lin and Chen, {Chi Long} and Chao, {Pin Zhir} and Chiou, {Jeng Fong} and Kuo, {Chia Chun} and Lee, {Fei Peng} and Lin, {Yung Feng} and Sung, {Yu Hsuan} and Lin, {Yun Tien} and Li, {Chang Fan} and Chen, {Yin Ju} and Chen, {Chien Ho}",
year = "2015",
doi = "10.18632/oncotarget.4521",
language = "English",
volume = "6",
pages = "26946--26959",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "29",

}

TY - JOUR

T1 - Targeting annexin A2 reduces tumorigenesis and therapeutic resistance of nasopharyngeal carcinoma

AU - Chen, Chang Yu

AU - Lin, Yong-Song

AU - Chen, Chi Long

AU - Chao, Pin Zhir

AU - Chiou, Jeng Fong

AU - Kuo, Chia Chun

AU - Lee, Fei Peng

AU - Lin, Yung Feng

AU - Sung, Yu Hsuan

AU - Lin, Yun Tien

AU - Li, Chang Fan

AU - Chen, Yin Ju

AU - Chen, Chien Ho

PY - 2015

Y1 - 2015

N2 - The expression of annexin A2 (ANXA2) in nasopharyngeal carcinoma (NPC) cells induces the immunosuppressive response in dendritic cells; however, the oncogenic effect and clinical significance of ANXA2 have not been fully investigated in NPC cells. Immunohistochemical staining for ANXA2 was performed in 61 patients and the association with clinicopathological status was determined. Short hairpin (sh)RNA knockdown of ANXA2 was used to examine cellular effects of ANXA2, by investigating alterations in cell proliferation, migration, invasion, adhesion, tube-formation assay, and chemo- and radiosensitivity assays were performed. RT-qPCR, Western blotting, and immunofluorescence were applied to determine molecular expression levels. Clinical association studies showed that the expression of ANXA2 was significantly correlated with metastasis (p = 0.0326) and poor survival (p = 0.0256). Silencing of ANXA2 suppressed the abilities of cell proliferation, adhesion, migration, invasion, and vascular formation in NPC cell. ANXA2 up-regulated epithelial-mesenchymal transition associated signal proteins. Moreover, ANXA2 reduced sensitivities to irradiation and chemotherapeutic drugs. These results define ANXA2 as a novel prognostic factor for malignant processes, and it can serve as a molecular target of therapeutic interventions for NPC.

AB - The expression of annexin A2 (ANXA2) in nasopharyngeal carcinoma (NPC) cells induces the immunosuppressive response in dendritic cells; however, the oncogenic effect and clinical significance of ANXA2 have not been fully investigated in NPC cells. Immunohistochemical staining for ANXA2 was performed in 61 patients and the association with clinicopathological status was determined. Short hairpin (sh)RNA knockdown of ANXA2 was used to examine cellular effects of ANXA2, by investigating alterations in cell proliferation, migration, invasion, adhesion, tube-formation assay, and chemo- and radiosensitivity assays were performed. RT-qPCR, Western blotting, and immunofluorescence were applied to determine molecular expression levels. Clinical association studies showed that the expression of ANXA2 was significantly correlated with metastasis (p = 0.0326) and poor survival (p = 0.0256). Silencing of ANXA2 suppressed the abilities of cell proliferation, adhesion, migration, invasion, and vascular formation in NPC cell. ANXA2 up-regulated epithelial-mesenchymal transition associated signal proteins. Moreover, ANXA2 reduced sensitivities to irradiation and chemotherapeutic drugs. These results define ANXA2 as a novel prognostic factor for malignant processes, and it can serve as a molecular target of therapeutic interventions for NPC.

KW - Annexin A2 (ANXA2)

KW - Chemotherapy

KW - Epithelial-mesenchymal transition (EMT)

KW - Nasopharyngeal carcinoma (NPC)

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84944459557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944459557&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.4521

DO - 10.18632/oncotarget.4521

M3 - Article

C2 - 26196246

AN - SCOPUS:84944459557

VL - 6

SP - 26946

EP - 26959

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 29

ER -